Versant V Luxco S.a R.l. - Net Worth and Insider Trading

Versant V Luxco S.a R.l. Net Worth

The estimated net worth of Versant V Luxco S.a R.l. is at least $506,347 dollars as of 2024-11-10. Versant V Luxco S.a R.l. is the 10% Owner of Aprea Therapeutics Inc and owns about 142,633 shares of Aprea Therapeutics Inc (APRE) stock worth over $506,347. Details can be seen in Versant V Luxco S.a R.l.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Versant V Luxco S.a R.l. has not made any transactions after 2019-10-07 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Versant V Luxco S.a R.l.

To

Versant V Luxco S.a R.l. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Versant V Luxco S.a R.l. owns 1 companies in total, including Aprea Therapeutics Inc (APRE) .

Click here to see the complete history of Versant V Luxco S.a R.l.’s form 4 insider trades.

Insider Ownership Summary of Versant V Luxco S.a R.l.

Ticker Comapny Transaction Date Type of Owner
APRE Aprea Therapeutics Inc 2020-04-09 10 percent owner

Versant V Luxco S.a R.l. Latest Holdings Summary

Versant V Luxco S.a R.l. currently owns a total of 1 stock. Versant V Luxco S.a R.l. owns 142,633 shares of Aprea Therapeutics Inc (APRE) as of October 7, 2019, with a value of $506,347.

Latest Holdings of Versant V Luxco S.a R.l.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
APRE Aprea Therapeutics Inc 2019-10-07 142,633 3.55 506,347

Holding Weightings of Versant V Luxco S.a R.l.


Versant V Luxco S.a R.l. Form 4 Trading Tracker

According to the SEC Form 4 filings, Versant V Luxco S.a R.l. has made a total of 0 transactions in Aprea Therapeutics Inc (APRE) over the past 5 years. The most-recent trade in Aprea Therapeutics Inc is the acquisition of 16,667 shares on October 7, 2019, which cost Versant V Luxco S.a R.l. around $5 Million.

Insider Trading History of Versant V Luxco S.a R.l.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Versant V Luxco S.a R.l. Trading Performance

GuruFocus tracks the stock performance after each of Versant V Luxco S.a R.l.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Versant V Luxco S.a R.l. is 115.11%. GuruFocus also compares Versant V Luxco S.a R.l.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Versant V Luxco S.a R.l. within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Versant V Luxco S.a R.l.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Versant V Luxco S.a R.l.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 19.41 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 14.43 LIMIT LIMIT LIMIT LIMIT LIMIT

Versant V Luxco S.a R.l. Ownership Network

Ownership Network List of Versant V Luxco S.a R.l.

No Data

Ownership Network Relation of Versant V Luxco S.a R.l.

Insider Network Chart

Versant V Luxco S.a R.l. Owned Company Details

What does Aprea Therapeutics Inc do?

Who are the key executives at Aprea Therapeutics Inc?

Versant V Luxco S.a R.l. is the 10 percent owner of Aprea Therapeutics Inc. Other key executives at Aprea Therapeutics Inc include President & CEO Oren Gilad , SrVP/CFO/Prin. Fin &Acctg. Off John P. Hamill , and director & President & CEO Christian S Schade .

Aprea Therapeutics Inc (APRE) Insider Trades Summary

Over the past 18 months, Versant V Luxco S.a R.l. made no insider transaction in Aprea Therapeutics Inc (APRE). Other recent insider transactions involving Aprea Therapeutics Inc (APRE) include a net purchase of 3,900 shares made by Oren Gilad , a net purchase of 26,957 shares made by Bernd R. Seizinger , and a net purchase of 23,728 shares made by Marc Duey .

In summary, during the past 3 months, insiders sold 6,462 shares of Aprea Therapeutics Inc (APRE) in total and bought 42,590 shares, with a net purchase of 36,128 shares. During the past 18 months, 6,462 shares of Aprea Therapeutics Inc (APRE) were sold and 69,417 shares were bought by its insiders, resulting in a net purchase of 62,955 shares.

Aprea Therapeutics Inc (APRE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Aprea Therapeutics Inc Insider Transactions

No Available Data

Versant V Luxco S.a R.l. Mailing Address

Above is the net worth, insider trading, and ownership report for Versant V Luxco S.a R.l.. You might contact Versant V Luxco S.a R.l. via mailing address: 15, Boulevard F.w. Raiffeisen, Luxembourg N4 L-2411.